Biogen Inc. $BIIB Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC lessened its holdings in Biogen Inc. (NASDAQ:BIIB) by 17.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 197,164 shares of the biotechnology company’s stock after selling 41,394 shares during the period. ProShare Advisors LLC owned about 0.13% of Biogen worth $27,619,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BIIB. Privium Fund Management B.V. purchased a new stake in shares of Biogen during the 2nd quarter valued at about $2,666,000. Nordea Investment Management AB boosted its holdings in Biogen by 5.7% in the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock worth $15,810,000 after acquiring an additional 6,811 shares during the period. Convergence Investment Partners LLC acquired a new stake in Biogen in the third quarter valued at approximately $1,342,000. Pitcairn Co. purchased a new stake in shares of Biogen during the second quarter valued at approximately $936,000. Finally, Fluent Financial LLC purchased a new stake in shares of Biogen during the third quarter valued at approximately $3,578,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BIIB shares. TD Cowen upped their target price on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday. Robert W. Baird cut their price objective on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Wedbush upped their price objective on shares of Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research report on Monday. Guggenheim lifted their target price on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Biogen in a research note on Monday. Thirteen research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat, Biogen currently has a consensus rating of “Hold” and an average target price of $207.81.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

Biogen Price Performance

BIIB opened at $188.99 on Wednesday. The company has a market capitalization of $27.74 billion, a P/E ratio of 21.45, a PEG ratio of 1.55 and a beta of 0.16. The company has a 50-day moving average of $177.44 and a 200-day moving average of $157.89. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $202.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same quarter last year, the company posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.